Last reviewed · How we verify
Experimental vaccine 2
Experimental vaccine 2, developed by Sinovac Research and Development Co., Ltd., is currently marketed but lacks specified primary indication and revenue data. A key strength is the protection of its core composition patent, which expires in 2028, providing a period of exclusivity. The primary risk is the unspecified competitive landscape, which may pose challenges without clear differentiation or market leadership data.
At a glance
| Generic name | Experimental vaccine 2 |
|---|---|
| Sponsor | Sinovac Research and Development Co., Ltd. |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
- A Study to Learn About mRNA Vaccines Against Influenza in Adults (PHASE2)
- The Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells) (PHASE1)
- Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above (PHASE3)
- A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus. (PHASE1)
- Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above (PHASE2)
- Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental vaccine 2 CI brief — competitive landscape report
- Experimental vaccine 2 updates RSS · CI watch RSS
- Sinovac Research and Development Co., Ltd. portfolio CI